May. 6 at 3:09 PM
$TRIB 🚨
I get the criticism:
“Same old Trinity story. Big potential. No follow-through.”
Fair.
But this time the setup has to be judged by what changes next, not what disappointed investors in the past.
✅ HIV production scaling back up
✅ New North America commercial lead added
✅ Core business aiming for revenue/profitability improvement
✅ Perceptive still involved
✅ CGM+ still the major wildcard
Nobody is saying management gets a free pass. They have to prove it.
But that is exactly why the valuation is where it is.
If revenue starts ticking up and CGM+ gets any credible validation, partner update, or pivotal trial progress, sentiment could flip fast.
The market is pricing in complete failure.
So the real question is this:
Is
$TRIB still the same old story… or are we finally seeing the first signs of a turnaround? 👀
